

CLAIMS

What is claimed is:

1. A method of treating glycogen storage disease type II in an individual,
comprising administering to the individual a therapeutically effective amount of
human acid α -glucosidase at a regular interval.
2. The method of Claim 1, wherein the glycogen storage disease type II is infantile
glycogen storage disease type II.
3. The method of Claim 1, wherein the glycogen storage disease type II is juvenile
glycogen storage disease type II.
4. The method of Claim 1, wherein the glycogen storage disease type II is adult-
onset glycogen storage disease type II.
5. The method of Claim 1, wherein the therapeutically effective amount of human
acid α -glucosidase is less than about 15 mg of acid α -glucosidase per kilogram
of body weight of the individual.
6. The method of Claim 5, wherein the therapeutically effective amount of human
acid α -glucosidase is about 1-10 mg of acid α -glucosidase per kilogram of body
weight of the individual.
7. The method of Claim 5, wherein the therapeutically effective amount of human
acid α -glucosidase is about 5 mg of acid α -glucosidase per kilogram of body
weight of the individual.

8. The method of Claim 1, wherein the human acid α -glucosidase is recombinant human acid α -glucosidase.
9. The method of Claim 1, wherein the human acid α -glucosidase is a precursor of recombinant human acid α -glucosidase.
- 5 10. The method of Claim 9, wherein the recombinant human acid α -glucosidase is produced in Chinese hamster ovary cells.
11. The method of Claim 1, wherein the regular interval is monthly.
12. The method of Claim 1, wherein the regular interval is bimonthly.
13. The method of Claim 1, wherein the regular interval is weekly.
- 10 14. The method of Claim 1, wherein the regular interval is twice weekly.
15. The method of Claim 1, wherein the regular interval is daily.
16. The method of Claim 1, wherein the human acid α -glucosidase is administered intravenously.
17. The method of Claim 1, wherein the human acid α -glucosidase is administered intramuscularly.
- 15 18. The method of Claim 1, wherein the human acid α -glucosidase is administered intrathecally or intraventricularly.

24-

19. The method of Claim 1, wherein the human acid α -glucosidase is administered in conjunction with an immunosuppressant.
20. The method of Claim 19, wherein the immunosuppressant is administered prior to any administration of human acid α -glucosidase to the individual.
- 5 21. A method of treating cardiomyopathy associated with glycogen storage disease type II in an individual, comprising administering to the individual a therapeutically effective amount of human acid α -glucosidase at a regular interval.
- 10 22. A pharmaceutical composition comprising human acid α -glucosidase in a container with a label containing instructions for administration of the composition for treatment of glycogen storage disease type II.

T00T20T340000